ZUNVEYL's commercial ramp in long-term care sets the stage for a sublingual line extension, but path hinges on whether revenue scales faster than burn

Alpha Cognition is a commercial-stage biopharmaceutical company whose lead product, ZUNVEYL, treats mild-to-moderate Alzheimer's disease and is already approved.

ZUNVEYL (buntanetap), a cholinesterase and protein translation inhibitor, is commercially launched for mild-to-moderate Alzheimer's in long-term care, with a sublingual formulation targeting dysphagia patients in development. The thesis resolves on whether ZUNVEYL revenue scales sufficiently to reduce financing dependency before the sublingual program requires material clinical investment. The primary competitive risk is displacement by anti-amyloid disease-modifying therapies — lecanemab and donanemab — which may reshape prescriber and payer prioritization in the overlapping mild AD population.